article thumbnail

Body mass index impacts the lipid-lowing effects of statins in patients with type 2 diabetes

Frontiers in Cardiovascular Medicine

BackgroundIndividuals diagnosed with type 2 diabetes mellitus (T2DM) commonly exhibit elevated lipid levels and an increased body mass index (BMI). The impact of BMI on the efficacy of statins in reducing lipid levels among diabetic patients remains uncertain.

BMI 52
article thumbnail

Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes

Cardiovascular Diabetology

Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce. Individuals with diabetes had a 1.5-fold fold higher mean expenditure that those without diabetes. individuals aged ≥ 18 years.

article thumbnail

Key Updates in the 2025 American Diabetes Association (ADA) Diabetes Guidelines 

Cardiometabolic Health Congress

Last month, the 2025 American Diabetes Association (ADA) guidelines were introduced, providing updates for diagnosing and managing diabetes and prediabetes. This ensures patients have contingency plans to maintain effective diabetes management during periods of unavailability.

article thumbnail

Hypoglycemic Events May Trigger Acute Ischemic Stroke Within 30 Days in Those With Diabetes: A Case-Crossover Study

Stroke Journal

We used conditional logistical regression models to estimate odds ratios and 95% CIs.RESULTS:There were 237 667 index admissions with AIS and diabetes during the study period. These results, if confirmed in other studies, emphasize the importance of avoiding hypoglycemic events in patients with diabetes.

article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

You Are Being Lied To About Cholesterol & Heart Disease.

Dr. Paddy Barrett

Non-smoker, doesn’t have diabetes and is on no medications. I'm Interested 1 Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. Here is a typical patient I might see in my clinical practice. 40 year old male with a family history of heart disease. LDL cholesterol = 4 mmol/l ( 155 mg/dl).

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”